TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10485720
Drug: Zidovudine 600
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 600 mg orally to the mother at onset of labour and 300 mg every 3 h until delivery, and 4 mg/kg orally twice daily to babies for 7 days after birth
Study: 6128282
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pseudoephedrine and triprolidine administered every 6 hours
Study: 24290597
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (600 mg of elemental Ca/d as CaCO3)
Study: 8841863
Drug: Continuous thoracic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous thoracic paravertebral infusion of bupivacaine (loading dose of 15 mL of 0.375% bupivacaine, plus an infusion of 5 mL of 0.25% bupivacaine every hour)
Study: 8841863
Drug: Bolus regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus regimen of 20 mL of 0.375% bupivacaine every 6 hours
Study: 1536215
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg micronized 17 beta-estradiol
Study: 1536215
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg micronized 17 beta-estradiol
Study: 1536215
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg micronized 17 beta-estradiol
Study: 1536215
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg micronized 17 beta-estradiol (after double-blind phase)
Study: 6369979
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral nonabsorbable antibiotics
Study: 31008751
Drug: Dexmedetomidine 0
Normalized name: dexmedetomidine 0.12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0 µg/kg (control)
Study: 24616335
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg) or Amlodipine (5 mg)
Study: 24616335
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (Aliskiren + Hydrochlorothiazide or Amlodipine)
Study: 22081150
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg bevacizumab
Study: 17203360
Drug: Chronic use
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic use of antibiotics
Study: 9370765
Drug: Oral resources
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral resources
Study: 22795164
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 10mg/kg dexamethasone intravenously at the beginning of the operation and 24 hours after (Group II)
Study: 22795164
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 10mg/kg dexamethasone intravenously at the beginning of the operation, before osteotomy, and 24 hours after (Group III)
Study: 18206133
Drug: Myofeedback training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofeedback training in combination with ergonomic counselling (Mfb/EC)
Study: 16897249
Drug: Neurotropin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurotropin (3 ml) combined with saline (3 ml)
Study: 16897249
Drug: 1% Mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Mepivacaine (6 ml)
Study: 10954955
Drug: Cefdinir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir (300 mg twice daily for 5 days)
Study: 10954955
Drug: Loracarbef (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef (400 mg twice daily for 7 days)
Study: 8769695
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydroxyurea and interferon alpha
Study: 1376577
Drug: Ampicillin/Metronidazole combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/Metronidazole combination
Study: 29570512
Drug: Effervescent paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent paracetamol (1 g three times a day)
Study: 29570512
Drug: Noneffervescent paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noneffervescent paracetamol
Study: 29570512
Drug: Effervescent paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent paracetamol
Study: 20466589
Drug: Pregabalin 50
Normalized name: pregabalin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 50 mg/day
Study: 20466589
Drug: Pregabalin 100
Normalized name: pregabalin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 100 mg/day
Study: 18603250
Drug: Intrauterine instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine instillation of 5 mL of 1% lignocaine 2 minutes prior to the procedure
Study: 18603250
Drug: Oral naproxen
Normalized name: naproxen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naproxen 375 mg self-administered 1 hour prior to HSG
Study: 16160876
Drug: SR bupropion
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR bupropion (300 mg/day)
Study: 11693589
Drug: Child training
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child training treatment group (CT) utilizing the Incredible Years Dinosaur Social Skills and Problem Solving Curriculum
Study: 11693589
Drug: Child training
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child training treatment group (CT)
Study: 8116059
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin A
Study: 3553455
Drug: Antibiotics (cefazolin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (cefazolin and gentamicin) administered in the immediate preoperative and intraoperative periods
Study: 3553455
Drug: Antibiotics (cefazolin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (cefazolin and gentamicin)
Study: 30160499
Drug: Low risk
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low risk drinking during treatment
Study: 30160499
Drug: Mostly abstinent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mostly abstinent during treatment
Study: 30160499
Drug: Heavy drinking
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy drinking during treatment
Study: 24906406
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy delivered by healthcare assistants
Study: 21287460
Drug: 0.5% nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% nifedipine cream for 4 weeks
Study: 21287460
Drug: Stool softeners
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stool softeners and 2% lidocaine cream for 4 weeks
Study: 10710823
Drug: New Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Cyclosporine A microemulsion formulation
Study: 2117054
Drug: Transdermal glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl trinitrate (GTN patches)
Study: 30836807
Drug: HBOT (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBOT (20‐40 sessions) plus conventional treatment
Study: 22537541
Drug: Hypofractionation (62
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionation (62 Gy at 3.1 Gy per fraction in 5 weeks) + 9-month androgen deprivation therapy
Study: 22537541
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation (80 Gy at 2 Gy per fraction in 8 weeks) + 9-month androgen deprivation therapy
Study: 16446682
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (5 g creatine monohydrate, 4 times daily for 6 days)
Study: 11081314
Drug: Aldactone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldactone (200 mg i.v.)
Study: 11081314
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 mg i.v.)
Study: 8671857
Drug: CsA (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA (7.5 mg/kg. b.i.d. in olive oil)
Study: 4096205
Drug: 1% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% pilocarpine solution with nasolacrimal obstruction (NLO)
Study: 4096205
Drug: 1% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% pilocarpine solution with eyelid closure (EC)
Study: 4096205
Drug: 1% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% pilocarpine solution with both NLO and EC
Study: 4096205
Drug: 1% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% pilocarpine solution with neither NLO nor EC
Study: 4096205
Drug: 3% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% pilocarpine ointment
Study: 4096205
Drug: 1% pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% pilocarpine solution
Study: 30907209
Drug: 600 µg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 µg of misoprostol (oral or vaginal)
Study: 30907209
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 mg vitamin B6)
Study: 26813359
Drug: PEGylated human
Normalized name: Pegylated human c-peptide
DrugBank: Pegylated synthetic human c-peptide (DB16283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGylated human recombinant hyaluronidase (PEGPH20) at doses of 1.0 μg/kg (n = 4), 1.6 μg/kg (n = 4), or 3.0 μg/kg (n = 20) in combination with gemcitabine (Gem)
Study: 26813359
Drug: PEGPH20 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGPH20 in combination with Gem for patients with high hyaluronan (HA) levels
Study: 26813359
Drug: PEGPH20 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGPH20 in combination with Gem for patients with low hyaluronan (HA) levels
Study: 9825371
Drug: i.v. propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. propafenone (PFN) (2 mg/kg bolus followed by 0.0078 mg/kg/min infusion)
Study: 9825371
Drug: o.s. propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: o.s. propafenone (PFN) (600 mg)
Study: 2681717
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin (anti-embolism stockings)
Study: 1090708
Drug: Major tranquilizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Major tranquilizer (neuroleptic) treatment
Study: 1090708
Drug: Therapy resistant
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy resistant schizophrenic patients
Study: 29363217
Drug: Oxycodone 15
Normalized name: oxyCODONE 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 15 mg
Study: 27509214
Drug: L-PRF socket
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF socket filling
Study: 25362008
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg/5 mL elemental zinc as zinc sulfate) for 2 weeks
Study: 25362008
Drug: Placebo (syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (syrup base) for 2 weeks
Study: 22674156
Drug: Intravenous butorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous butorphanol (1 mg loading dose followed by 0.2 mg/h infusion)
Study: 22674156
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline (infusion of the same volume)
Study: 20299607
Drug: Eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 50 mg/d
Study: 12675179
Drug: Vecuronium bromide
Normalized name: Vecuronium Bromide
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium bromide (0.015 mg/kg) followed by repeat dose (0.08 mg/kg) at peak D1 suppression
Study: 12675179
Drug: Vecuronium bromide
Normalized name: Vecuronium Bromide
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium bromide (0.08 mg/kg) at peak DBS ratio suppression
Study: 10326708
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity training (30 minutes daily biking on an ergometer in supine position)
Study: 27899400
Drug: Sertraline (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (titrated up to a maximum of 100 mg daily over 28 days)
Study: 25099071
Drug: Yogurt drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt drink with added plant stanol esters (4 g)
Study: 9658375
Drug: Combined hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined hepatitis A/hepatitis B vaccine (3 injections at 0, 1, and 6 months)
Study: 8017413
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg immediate-release lithium carbonate tablets (Lithotab)
Study: 8017413
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg extended-release lithium carbonate tablets (Eskalith CR)
Study: 8017413
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg extended-release lithium carbonate tablets (Lithobid)
Study: 162924
Drug: Cytosine arabinoside
Normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytosine arabinoside (3 mg/kg every 24 hr for up to 7 days)
Study: 19446144
Drug: Lidocaine patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Lidocaine Patch]
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine patch applied to the trigger point for 4 days (total daily dose, 350 mg)
Study: 19446144
Drug: Infiltration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration of the trigger point with two 1-mL injections of 0.5% bupivacaine hydrochloride given 2 days apart
Study: 19446144
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch applied to the trigger point for 4 days
Study: 17308963
Drug: Reviparin (Clivarin)
Normalized name: reviparin
DrugBank: Reviparin (DB09259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reviparin (Clivarin) 3,436 IU anti-Xa/0.6 ml, self-administered twice daily for 8 weeks
Study: 15111849
Drug: Dacron patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacron patch (Hemashield Finesse) closure
Study: 10389549
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 micrograms
Study: 1739321
Drug: Intensive individual
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive individual speech therapy
Study: 1739321
Drug: Weekly speech
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly speech therapy
Study: 23708466
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50 or 70 mg
Study: 15671215
Drug: Oral L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-arginine (12 g/d for 3 wk)
Study: 12509647
Drug: Zincum gluconicum
Normalized name: Zincum Gluconicum 1 X Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zincum gluconicum nasal gel (33 mmol/l), administered four times daily until symptoms resolved, for a maximum of 10 days.
Study: 12509647
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal gel, administered four times daily until symptoms resolved, for a maximum of 10 days.
Study: 12509647
Drug: Zincum gluconicum
Normalized name: Zincum Gluconicum 1 X Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zincum gluconicum nasal gel
Study: 12509647
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal gel
Study: 1642912
Drug: Inhalation technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation technique (propofol and alfentanil followed by nitrous oxide and isoflurane)
Study: 6443759
Drug: Piroxicam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam (40 mg for the first 2 days, then 20 mg daily)
Study: 29878617
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injections (n=45)
Study: 29878617
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) injections (n=44)
Study: 25252255
Drug: Sealed in-office
Normalized name: GOLDEN SEAL
DrugBank: Goldenseal (DB16594)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sealed in-office bleaching technique using 35% hydrogen peroxide gel for a single 45-min application.
Study: 25252255
Drug: Conventional in-office
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional in-office bleaching technique using 35% hydrogen peroxide gel for a single 45-min application.
Study: 23249399
Drug: Group psychoeducational
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychoeducational program (12 weekly sessions of 1.5 hours each led by two nurses)
Study: 14583178
Drug: Aldose reductase
Normalized name: Aldose reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldose reductase inhibitor (ARI); administration details not specified
Study: 9987171
Drug: Hepagene vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepagene vaccine (5, 10, 20, and 40 micrograms/ml)
Study: 9987171
Drug: Hepagene vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepagene vaccine (5 micrograms/ml)
Study: 9987171
Drug: Hepagene vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepagene vaccine (10 micrograms/ml or more)
Study: 9987171
Drug: Repeated 'S'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated 'S' containing vaccines
Study: 8341891
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methamphetamine (40-60 mg)
Study: 8341891
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methamphetamine (20 mg)
Study: 8341891
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (5 or 10 mg methamphetamine)
Study: 3521691
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg orally with naloxone intravenously
Study: 3521691
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg orally with 0.9% saline vehicle (placebo) intravenously
Study: 27605230
Drug: Celecoxib (COX-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (COX-2 inhibitor) for 4 weeks postoperatively
Study: 27605230
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no COX-2 inhibitor)
Study: 22045673
Drug: PEG-IFNα-2a 180
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFNα-2a 180 μg/week for 48 weeks
Study: 22045673
Drug: PEG-IFNα-2a 90
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFNα-2a 90 μg/week for 24 weeks
Study: 22045673
Drug: PEG-IFNα-2a 90
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFNα-2a 90 μg/week for 48 weeks
Study: 22045673
Drug: PEG-IFNα-2a 180
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFNα-2a 180 μg/week for 24 weeks
Study: 20087260
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with 4 cycles of carboplatine and etoposide followed by conformal radiotherapy (RT)
Study: 20087260
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment with cisplatine and etoposide and conformal RT followed by two cycles of consolidation chemotherapy of carboplatine and etoposide
Study: 11301846
Drug: Gemcitabine in
Normalized name: gemcitabine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine in combination with cisplatin
Study: 30488617
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg twice a day) plus Amantadine (100 mg daily)
Study: 30488617
Drug: Fluvoxamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100 mg twice a day) plus Placebo
Study: 26151090
Drug: Roflumilast treatment
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast treatment
Study: 9408065
Drug: Losartan (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (12.5 mg once daily)
Study: 29764706
Drug: Rivaroxaban plus
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban plus an antiplatelet drug (aspirin, clopidogrel, or prasugrel)
Study: 22554994
Drug: Brushing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing with 200g force after acid and enzyme treatment
Study: 22554994
Drug: Brushing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing with 300g force after acid and enzyme treatment
Study: 22554994
Drug: Brushing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing with 400g force after acid and enzyme treatment
Study: 16194498
Drug: Monthly home
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly home visits with intercalated phone calls from trained nursing staff
Study: 10640164
Drug: MPA/E2C (Lunelle
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA/E2C (Lunelle Monthly Contraceptive Injection)
Study: 25963404
Drug: Flaxseed (FS)
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (FS) 40 g daily for 4 weeks